Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Structure Therapeutics Inc (GPCR)

Structure Therapeutics Inc (GPCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,997,395
  • Shares Outstanding, K 57,795
  • Annual Sales, $ 0 K
  • Annual Income, $ -122,530 K
  • EBIT $ -248 M
  • EBITDA $ -265 M
  • 60-Month Beta -1.64
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.46

Options Overview Details

View History
  • Implied Volatility 297.52% (+22.23%)
  • Historical Volatility 67.69%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 297.52% on 12/05/25
  • IV Low 59.22% on 09/15/25
  • Expected Move (DTE 12) 18.45 (53.37%)
  • Put/Call Vol Ratio 0.20
  • Today's Volume 11,816
  • Volume Avg (30-Day) 2,304
  • Put/Call OI Ratio 0.50
  • Today's Open Interest 46,232
  • Open Int (30-Day) 36,613
  • Expected Range 16.12 to 53.01

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.36
  • Number of Estimates 7
  • High Estimate -0.29
  • Low Estimate -0.42
  • Prior Year -0.22
  • Growth Rate Est. (year over year) -63.64%

Price Performance

See More
Period Period Low Period High Performance
1-Month
30.94 +11.70%
on 12/04/25
40.29 -14.22%
on 11/19/25
+2.35 (+7.30%)
since 11/05/25
3-Month
20.04 +72.46%
on 09/16/25
40.29 -14.22%
on 11/19/25
+12.48 (+56.52%)
since 09/05/25
52-Week
13.22 +161.42%
on 04/09/25
40.29 -14.22%
on 11/19/25
+3.32 (+10.63%)
since 12/05/24

Most Recent Stories

More News
Structure Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights

Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025 Oral small molecule amylin receptor agonist (ACCG-2671)...

GPCR : 34.56 (+5.21%)
Piper Sandler Keeps Their Buy Rating on Structure Therapeutics, Inc. Sponsored ADR (GPCR)

Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on Structure Therapeutics, Inc. Sponsored ADR today and set a price target of $93.00. The company’s shares closed yesterday at $26.62.Elevate...

GPCR : 34.56 (+5.21%)
Structure Therapeutics to Participate in Two Upcoming Healthcare Investor Conferences

SAN FRANCISCO, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic...

GPCR : 34.56 (+5.21%)
Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights

Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for year-end 2025 readouts Aleniglipron clinical development program expanded to...

GPCR : 34.56 (+5.21%)
Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671

GPCR : 34.56 (+5.21%)
Structure Therapeutics to Participate in Multiple Upcoming Healthcare Investor Conferences

GPCR : 34.56 (+5.21%)
Structure Therapeutics Reports First Quarter 2025 Financial Results and Recent Highlights

GPCR : 34.56 (+5.21%)
Wall Street Sees Pfizer's Weight-Loss Pill Exit As A Win For 2 Smaller Biotech Firms: Retail Turns Bullish

Investors are now considering the possibility of Pfizer acquiring either of these companies as it looks for external candidates.

VKTX : 38.55 (-0.05%)
GPCR : 34.56 (+5.21%)
PFE : 26.03 (+1.28%)
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Popped Today

Pfizer bows, but is not entirely out of the GLP-1 race.

VKTX : 38.55 (-0.05%)
NVO : 47.86 (-0.27%)
LLY : 1,010.31 (-0.41%)
GPCR : 34.56 (+5.21%)
PFE : 26.03 (+1.28%)
The State of Weight Loss Drugs

In this podcast, Motley Fool analyst Karl Thiel joins host Ricky Mulvey to check in on the GLP-1 landscape. They discuss:

GIS : 45.93 (-0.11%)
VKTX : 38.55 (-0.05%)
NVO : 47.86 (-0.27%)
HIMS : 39.20 (-2.05%)
LLY : 1,010.31 (-0.41%)
CAG : 17.05 (+0.59%)
GPCR : 34.56 (+5.21%)
ISRG : 575.34 (+1.18%)
PFE : 26.03 (+1.28%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company discovering and developing novel oral therapeutics to treat chronic metabolic and pulmonary diseases with unmet medical needs. Structure Therapeutics Inc. is based in SAN FRANCISCO.

See More

Key Turning Points

3rd Resistance Point 39.38
2nd Resistance Point 37.60
1st Resistance Point 36.08
Last Price 34.56
1st Support Level 32.78
2nd Support Level 30.99
3rd Support Level 29.47

See More

52-Week High 40.29
Last Price 34.56
Fibonacci 61.8% 29.95
Fibonacci 50% 26.76
Fibonacci 38.2% 23.56
52-Week Low 13.22

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar